Related Experiment Video
Updated: Mar 28, 2026

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells
Published on: November 21, 2025
Kidney Injury Molecule-1 and Cardiovascular Diseases: From Basic Science to Clinical Practice
Branislava Medić1, Branislav Rovčanin2, Gordana Basta Jovanović3
1Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 1, 11129 Belgrade, Serbia.
Insights
Kidney injury molecule-1 (KIM-1) shows promise for early detection of cardiovascular disease risk in patients with kidney problems. Monitoring KIM-1 may improve outcomes for those with cardiorenal conditions.
Area of Science:
- Nephrology
- Cardiology
- Biomarker Discovery
Background:
- Cardiovascular disease (CVD) is a leading cause of death in patients with kidney dysfunction, particularly acute kidney injury (AKI).
- Early identification of patients with combined renal and cardiovascular risk is crucial for timely intervention and improved outcomes.
- Kidney Injury Molecule-1 (KIM-1) is emerging as a significant biomarker for kidney damage.
Purpose of the Study:
- To review current literature on KIM-1's role in the early diagnosis and prognosis of cardiovascular diseases.
- To highlight KIM-1's potential as a predictive marker in cardiorenal conditions.
Main Methods:
- Literature review of animal and human studies on KIM-1.
- Analysis of KIM-1's established role in acute tubular necrosis (ATN) and AKI prediction.
- Exploration of KIM-1's relevance in cardiorenal syndromes and related cardiovascular conditions.
Main Results:
- KIM-1 is recognized as a key marker for acute tubular necrosis (ATN) and a predictor of AKI development and prognosis.
- The US FDA has approved KIM-1 as an AKI biomarker for preclinical drug development.
- Emerging data underscore KIM-1's importance in monitoring various renal diseases and cardiovascular conditions, including cardiorenal syndrome and heart failure.
Conclusions:
- KIM-1 is a promising biomarker for the early diagnosis and prediction of clinical outcomes in specific cardiovascular diseases.
- Further research into KIM-1 monitoring could enhance patient management in cardiorenal settings.
Abstract:
Despite the recent findings concerning pathogenesis and novel therapeutic strategies, cardiovascular disease (CVD) still stays the leading cause of morbidity and mortality in patients with renal dysfunction, especially acute kidney injury (AKI). Early detection of patients with impaired renal function with cardiovascular risk may help ensure more aggressive treatment and improve clinical outcome. Kidney injury molecule-1 (KIM-1) is a new, promising marker of kidney damage which is currently the focus of countless studies worldwide. Some recent animal and human studies established KIM-1 as an important marker of acute tubular necrosis (ATN) and reliable predictor of development and prognosis of AKI. Food and Drug Administration (FDA) in USA acclaimed KIM-1 as an AKI biomarker for preclinical drug development. Recent data suggest the importance of monitoring of KIM-1 for early diagnosis and clinical course not only in patients with various forms of AKI and other renal diseases but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, cardiothoracic surgical interventions in the pediatric emergency setting, and so forth. The aim of this review article is to summarize the literature data concerning KIM-1 as a potential novel marker in the early diagnosis and prediction of clinical outcome of certain cardiovascular diseases.
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care

